2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations

Canadian Journal of Cardiology

Volumn 25, Issue 10, 2009, Pages 567-579

  Genest, Jacques ^a   McPherson, Ruth ^b   Frohlich, Jiri ^c   Anderson, Todd ^d   Campbell, Norm ^d   Carpentier, André ^e   Couture, Patrick ^f   Dufour, Robert ^g   Fodor, George ^b   Francis, Gordon A ^c   Grover, Steven ^a   Gupta, Milan ^h   Hegele, Robert A ⁱ   Lau, David C ^j   Leiter, Lawrence ^k   Lewis, Gary F ^l   Lonn, Eva ^m   Mancini, G B John ⁿ   Ng, Dominic ^k   Pearson, Glen J ^o   Sniderman, Allan ^p   Stone, James A ^j   Ur, Ehud ⁿ   more..

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^c ST PAUL S HOSPITAL   (Canada)

^d LIBIN CARDIOVASCULAR INSTITUTE OF ALBERTA   (Canada)

^e CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^f LAVAL UNIVERSITY   (Canada)

^g CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^h MCMASTER UNIVERSITY   (Canada)

ⁱ ROBARTS RESEARCH INSTITUTE   (Canada)

^j UNIVERSITY OF CALGARY   (Canada)

^k ST MICHAEL'S HOSPITAL   (Canada)

^l UNIVERSITY OF TORONTO   (Canada)

^m MCMASTER UNIVERSITY   (Canada)

ⁿ UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^o UNIVERSITY OF ALBERTA   (Canada)

^p MCGILL UNIVERSITY   (Canada)

more..

Author keywords

Atherosclerosis; Cardiovascular risk factors; Cholesterol; Coronary artery disease; Dyslipidemia; Lipids; Secondary prevention

Indexed keywords

ACETYLSALICYLIC ACID; APOLIPOPROTEIN; ATORVASTATIN; BEZAFIBRATE; COLESTIPOL; COLESTYRAMINE; EZETIMIBE; FENOFIBRATE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

AGE DISTRIBUTION; ARTICLE; CALORIC INTAKE; CANADA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; DIABETES MELLITUS; DIET THERAPY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG SAFETY; DRY SKIN; DYSLIPIDEMIA; FAMILY HISTORY; FLUSHING; GASTRITIS; GENDER BIAS; GLYCEMIC CONTROL; HEART FAILURE; HEREDITY; HIGH RISK POPULATION; HUMAN; HYPERTRIGLYCERIDEMIA; IMMOBILIZATION; KIDNEY DISEASE; LIPOPROTEIN DEFICIENCY; METABOLIC SYNDROME X; MYOPATHY; NONHUMAN; NUTRITIONAL STATUS; OBESITY; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PROTEIN BLOOD LEVEL; RECOMMENDED DRUG DOSE; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SMOKING CESSATION;

EID: 70350360003     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(09)70715-9     Document Type: Article

References (79)

1. Heart and Stroke Foundation of Canada. The Growing Burden of Heart Disease and Stroke in Canada 2003. (Version current at August 13, 2009).
2. Statistics Canada. CANSIM. (Version current at August 13, 2009).
3. McPherson R, Frohlich J, Fodor G, Genest J; Canadian Cardiovascular Society. Canadian Cardiovascular Society position statement - recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol 2006;22:913-27.
4. Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE. Non-HDL cholesterol, apolipoproteins A-I and B-100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA 2005;294:326-33.
5. Ridker PM, Danielson E, Fonseca FA, et al; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207.
6. Lloyd-Jones DM, Nam BH, D'Agostino RB, et al. Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults - a prospective study of parents and offspring. JAMA 2004;291:2204-11.
7. Friedlander Y, Siscovick DS, Weinmann S, et al. Family history as a risk factor for primary cardiac arrest. Circulation 1998;97:155-60.
8. Després JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006;444:881-7.
9. Katzmarzyk PT, Mason C. Prevalence of class I, II and III obesity in Canada. CMAJ 2006;174:156-7.
10. Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome - a new worldwide definition. Lancet 2005;366:1059-62.
11. Ward MM. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum 1999;42:338-46.
12. Gladman DD, Ang M, Su L, Tom BD, Schentag CT, Farewell VT. Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis 2009;68:1131-5.
13. Thorburn CM, Ward MM. Hospitalizations for coronary artery disease among patients with systemic lupus erythematosus. Arthritis Rheum 2003;48:2519-23.
14. Dorn SD, Sandler RS. Inflammatory bowel disease is not a risk factor for cardiovascular disease mortality: Results from a systematic review and meta-analysis. Am J Gastroenterol 2007;102:662-7.
15. Bernstein CN, Wajda A, Blanchard JF. The incidence of arterial thromboembolic diseases in inflammatory bowel disease: A population-based study. Clin Gastroenterol Hepatol 2008;6:41-5.
16. DAD Study Group; Friis-Møller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007;356:1723-35.
17. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.
18. The SEARCH Study. (Version current at August 13, 2009).
19. Fruchart JC, Sacks F, Hermans MP, et al. The residual risk reduction initiative: A call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol 2008;102(10 Suppl):1K-34K.
20. Johnson C, Waters DD, DeMicco DA, et al. Comparison of effectiveness of atorvastatin 10 mg versus 80 mg in reducing major cardiovascular events and repeat revascularization in patients with previous percutaneous coronary intervention (post hoc analysis of the Treating to New Targets [TNT] Study). Am J Cardiol 2008;102:1312-7.
21. Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med 2007;356:2388-98.
22. Lonn E, Yusuf S, Arnold MJ, et al; Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006;354:1567-77.
23. Smith SC Jr, Allen J, Blair SN, et al; AHA/ACC; National Heart, Lung, and Blood Institute. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: Endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006;113:2363-72.
24. Yusuf S, Hawken S, Ounpuu S, et al; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet 2004;364:937-52.
25. Go AS, Chertow GM, Fan QJ, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-305.
26. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease - a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003;108:2154-69.
27. Barbaro G, Iacobellis G. Metabolic syndrome associated with HIV and highly active antiretroviral therapy. Curr Diab Rep 2009;9:37-42.
28. Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: A meta-analysis. Am J Med 2006;119:812-9.
29. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events. Circulation 2003;107:391-7.
30. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease - meta-analysis of prospective studies. Circulation 2000;102:1082-5.
31. Davidson MH, Corson MA, Alberts MJ, et al. Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. Am J Cardiol 2008;101:51F-57F.
32. NACB LMPG Committee Members; Myers GL, Christenson RH, Cushman M, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Emerging biomarkers for primary prevention of cardiovascular disease. Clin Chem 2009;55:378-84.
33. D'Agostino RB, Ramachandran SV, Pencina MJ, et al. General cardiovascular risk profile for use in primary care. The Framingham Heart Study. Circ 2008;117:743-53.
34. Grover SA, Lowensteyn I, Joseph L, et al; Cardiovascular Health Evaluation to Improve Compliance and Knowledge Among Uninformed Patients (CHECK-UP) Study Group. Patient knowledge of coronary risk profile improves the effectiveness of dyslipidemia therapy: The CHECK-UP study: A randomized controlled trial. Arch Intern Med 2007;167:2296-303.
35. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: The Reynolds Risk Score. JAMA 2007;297:611-9.
36. Ridker PM, Paynter NP, Rifai N, Gaziano JM, Cook NR. C-reactive protein and parental history improve global cardiovascular risk prediction: The Reynolds Risk Score for men. Circulation 2008;118:2243-51.
37. Michos ED, Blumenthal RS, Becker LC. Women with a Framingham risk score < 10 and a family history of premature CHD have a high prevalence of subclinical coronary atherosclerosis. Circulation 2004;110:790.
38. Lloyd-Jones DM. Short-term versus long-term risk for coronary artery disease: Implications for lipid guidelines. Curr Opin Lipidol 2006;17:619-25.
39. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: Full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007;14(Suppl 2):S1-113.
40. Leiter L, Genest J, Harris SB, et al. Dyslipidemia. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Can J Diabetes 2008;32(Suppl 1):S107-S114.
41. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels - results of AFCAPS/TexCAPS. JAMA 1998;279:1615-22.
42. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart-disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
43. Sever, PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet 2003;361:1149-58.
44. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002;360:7-22.
45. Anand SS, Yusuf S, Vuksan V, et al. Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: The Study of Health Assessment and Risk in Ethnic Groups (SHARE). Lancet 2000;356:279-84.
46. Kaler SN, Ralph-Campbell K, Pohar S, King M, Laboucan CR, Toth EL. High rates of the metabolic syndrome in a First Nations Community in western Canada: Prevalence and determinants in adults and children. Int J Circumpolar Health 2006;65:389-402.
47. Cannon CP, Braunwald E, Mccabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504.
48. Larosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35.
49. Wiviott SD, de Lemos JA, Cannon CP, et al. A tale of two trials: A comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22. Circulation 2006;113:1406-14.
50. Pedersen TR, Faergeman O, Kastelein JJP, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: The IDEAL study: A randomized controlled trial. JAMA 2005;294:2437-45.
51. Murphy SA, Cannon CP, Wiviott SD, et al. Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy - Thrombolysis in Myocardial Infarction 22 trials). Am J Cardiol 2007;100:1047-51.
52. Thompson GR, Hollyer J, Waters DD. Percentage change rather than plasma level of LDL-cholesterol determines therapeutic response in coronary heart disease. Curr Opin Lipidol 1995;6:386-8.
53. Barret PJ, Ballantyne CM, Carmena R, et al. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: Report of the Thirty-Person/Ten-Country Panel. J Intern Med 2006;259:247-58.
54. van der Steeg WA, Boekholdt SM, Stein EA, et al. Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: A case-control analysis in EPIC-Norfolk. Ann Intern Med 2007;146:640-8.
55. Nicholls SJ, Tuzcu EM, Sipahi I, et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 2007;297:499-508.
56. Kini AS, Muntner P, Moreno PR, et al. Relation of high-density lipoprotein cholesterol to mortality after percutaneous coronary interventions in patients with low-density lipoprotein <70 mg/dl. Am J Cardiol 2009;103:350-4.
57. Ridker PM, Danielson E, Fonseca FA, et al; on behalf of the JUPITER Trial Study Group. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: A prospective study of the JUPITER trial. Lancet 2009;373:1175-82.
58. Kjekshus J, Apetrel E, Barrios V, et al; CORONA Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007;357:2248-61.
59. Gissi-HF Investigators; Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): A randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1231-9.
60. Wanner C, Krane V, März W, et al; German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005;353:238-48.
61. Fellström BC, Jardine AG, Schmieder RE, et al; AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009;360:1395-407.
62. Ankle Brachial Index Collaboration; Fowkes FG, Murray GD, Butcher I, et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: A meta-analysis. JAMA 2008;300:197-208.
63. Greenland P, Gaziano JM. Clinical practice. Selecting asymptomatic patients for coronary computed tomography or electrocardiographic exercise testing. N Engl J Med 2003;349:465-73.
64. Stein JH, Korcarz CE, Hurst RT, et al; American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: A consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr 2008;21:93-111.
65. Greenland P, Bonow RO, Brundage BH, et al. ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: A report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography). Circulation 2007;115:402-26.
66. Miller JM, Rochitte CE, Dewey M, et al. Diagnostic performance of coronary angiography by 64-row CT. N Engl J Med 2008;359:2324-36.
67. Kloner RA, Rezkalla SH. To drink or not to drink? That is the question. Circulation 2007;116:1306-17.
68. Sacks FM, Bray GA, Carey VJ, et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med 2009;360:859-73.
69. Lichtman JH, Bigger JT Jr, Blumenthal JA, et al. Depression and coronary heart disease: Recommendations for screening, referral, and treatment: A science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: Endorsed by the American Psychiatric Association. Circulation 2008;118:1768-75.
70. Lespérance F, Frasure-Smith N, Koszycki D, et al; CREATE Investigators. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: The Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. JAMA 2007;297:367-79.
71. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237-45.
72. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341:410-8.
73. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet 2005;366:1849-61.
74. Frikke-Schmidt R, Nordestgaard BG, Stene MC, et al. Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA 2008;299:2524-32.
75. Alrasadi K, Awan K, Ruel I, et al. Comparison of treatment of severe high-density lipoprotein cholesterol deficiency in men with daily atorvastatin (20 mg) versus fenofibrate (200 mg) versus extended-release niacin (2 g). Am J Cardiol 2008;102:1341-7.
76. Barter PJ, Caulfield M, Eriksson M, et al; ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109-22.
77. Barter P, Gotto AM, LaRosa JC, et al; Treating to New Targets Investigators HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N. Engl J Med 2007;357:1301-10.
78. Brown BG, Zhao XQ. Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk. Am J Cardiol 2008;101:58B-62B. .
79. ClinicalTrials.gov. (Version current at August 13, 2009).